Category: Pharma

Make way for Retrodal, Preprexa and Preoquel

published date
October 3rd, 2006 by

Make way for Retrodal, Preprexa and Preoquel

J&J is smarter than it sometimes lets on. As reported earlier (Clarinex, Nexium, Nexperdal?), the company isn’t testing its ‘new and improved’ anti-psychotic, paliperidone against its soon-to-go-generic blockbuster Risperdal, because despite the hype there’s no reason to think paliperidone is better.

They’re also not testing paliperidone against older drugs, and here’s one reason why. From The Washington Post (In Antipsychotics, Newer Isn’t Better), subtitled –in an apparent attempt to be even more dramatic than the New York Times— “Drug Find Shocks Researchers” says:

Schizophrenia patients do as well, or perhaps even better, on older psychiatric drugs compared with newer and far costlier medications, according to a study published yesterday that overturns conventional wisdom about antipsychotic drugs, which cost the United States $10 billion a year.

The results are causing consternation. The researchers who conducted the trial were so certain they would find exactly the opposite that they went back to make sure the research data had not been recorded backward…

“The claims of superiority for the [newer drugs] were greatly exaggerated,” wrote Columbia University psychiatrist Jeffrey Lieberman. “This may have been encouraged by an overly expectant community of clinicians and patients eager to believe in the power of new medications. At the same time, the aggressive marketing of these drugs may have contributed to this enhanced perception of their effectiveness in the absence of empirical information.”

How long until someone dresses up one of the old drugs in a new formulation and demonstrates superiority over the newer classes?

Move over Risperdal, Zyprexa, and Seroquel. Make way for Retrodal, Preprexa and Preoquel!

And yes, Virginia it turns out there already is a Desperal, but still no Nexperdal or Ripofferdal.

Clarinex, Nexium, Nexperdal?

published date
September 29th, 2006 by

Clarinex, Nexium, Nexperdal?

J&J is stealing a play from AstraZeneca and Schering-Plough. AZ couldn’t come up with a worthy successor to Prilosec, so when the drug went off patent the company introduced the infamous Nexium, which is the substance the body turns Prilosec into. Basically you get Nexium when you swallow Prilosec, yet Nexium managed to become a multibillion product. Clarinex is just a tiny tweak on Claritin, introduced when Claritin’s patent expired.

Now J&J is faced with the expiration of its blockbuster for schizophrenia, Risperdal. When a patient takes Risperdal the body converts it to paliperidone. So just like AZ, J&J is going to market paliperidone as the next thing. J&J claims paliperidone is better than Risperdal, but that’s doubtful. From the Wall Street Journal:

The research backing J&J’s claims for paliperidone seems a little thin. Clinical tests, involving 1600 patients, pitted it against a sugar pill, not Risperdal or other antipsychotic drugs…

“They can’t claim its better than risperidone [Risperdal’s generic name] because they didn’t do the comparison,” said [Duke psychiatry professor] P. Murali Doraiswamy.

Basically, J&J is proving that paliperidone is better than nothing. That’s not a very high standard.

Meanwhile doctors, health plans, and patients haven’t set a very high standard either. Doctors continue to accept Nexium samples and prescribe the drug, most payers still have it on formulary, and patients continue to insist on the purple pill. Time to wise up!

J&J hasn’t picked a brand name for paliperidone yet. Here are a few suggestions:

  • Nexperdal
  • Ripofferdal
  • Desperal

Pharmacists should step up if doctors won’t

published date
September 28th, 2006 by

Pharmacists should step up if doctors won’t

From the Associated Press in the Wall Street Journal:

In recordings of 185 patient visits, doctors failed to mention a new drug’s side effects or how long to take the drug in about two-thirds of the visits. The research suggests that patients and their doctors must work harder, said Patrick O’Connor of HealthPartners Research Foundation in Minneapolis. “Patients need to ask, ‘‘What are the most important medicines in my treatment, the ones that will help me live long enough to see my grandchildren grow up?'”

That’s a nice quote Dr. O’Connor, but do you really expect docs to “work harder” and react positively when patients ask them such trite questions? My suggestion is to bring the pharmacist into the loop, to provide information at the time of dispensing and reinforcement at refill time. It would help if pharmacists had access to the patient’s medical record.

If pharmacists are too busy maybe the Phoenix police department can fill the gap.

Vaccines for non-fatal conditions

published date
September 26th, 2006 by

Vaccines for non-fatal conditions

From CNN (Vaccine aims to wipeout ear, sinus infections)

U.S. researchers said Tuesday that they are starting trials of a new vaccine aimed at wiping out childhood ear and sinus infections and many cases of bronchitis in adults.

Unlike virtually all other vaccines on the market, this one will not be aimed at saving lives, but at preventing nuisance illnesses, the researchers said.

“We are now in an era where we look to vaccines that make life better,” said Dr. Michael Pichichero, a professor of microbiology, immunology, pediatrics, and medicine at the University of Rochester Medical Center, who is leading the trial.

Now that we have developed technologies to fight fatal illnesses it is easier to use similar strategies for things that are troublesome but not life-threatening. Be on the lookout for similar advances in ADHD and PMS.

Thanks to Mickey.

Citigroup doesn’t think Wal-Mart price cut move is significant

published date
September 22nd, 2006 by

Citigroup doesn’t think Wal-Mart price cut move is significant

Yesterday’s price cut on generic drugs, led by Wal-Mart and quickly matched by others, shouldn’t have a big impact on other players in the pharmaceutical supply chain, according to Citigroup analyst Charles Boorady.

Upon perusal of [the list of drugs to be sold for $4] we find no change to our [earning estimates for PBMs] and therefore find the stock drop unwarranted. The vast majority are drugs PBMs bill and collected almost nothing for anyway because (1) were already low priced, (2) mostly acute drugs such as antibiotics and not maintenance meds, or (3) OTC drugs like multivitamins or pain meds

That narrow analysis is probably on target, but as I posted last night, the danger to payers is that it represents the beginning of the end of routine costs being paid by insurance, by making people see that it’s not worth the hassle. For example, here’s an excerpt of an email I received today from a family member:

I see in the paper today that K-Mart is offering generic drugs, including Atenolol, which I take, for $4 per 30 pills. After my insurance coverage does its thing, I pay $20 for 90 pills. Interesting.

That’s the kind of realization I’m talking about. Unlike Boorady, I don’t think the market oversold these stocks.